DIA/FDA Oligonucleotide-Based Therapeutics Conference

What is happening at Oligonucleotide-Based Therapeutics Conference

• Track 1: Clinical

There are more than a dozen oligonucleotide based products approved for therapeutic use and nearly 100 currently in clinical testing. Track 1 will explore the lessons learned and the ongoing challenges to clinical use of oligos. The Track sessions are divided by tissue, including kidney, brain, eye, liver and other extrahepatic. Another session will cover Clinical Pharmacology and a special concurrent session will cover Individualized ASO Products.

• Track 2: Non Clinical

The nonclinical track will focus on development and safety assessments of oligonucleotide-based therapeutics. A variety of modalities, routes of administration, and methodologies will be discussed.

• Track 3: CMC

This track provides an interactive forum for innovators and regulators to present and discuss cutting edge topics in oligonucleotide chemistry, manufacturing, and controls (CMC). The track emphasizes topics that are emerging (e.g., use of platform knowledge, ICH Q14, new oligonucleotide modalities) and will require ongoing collaboration with global regulators. Attendees will take away a deeper understanding of key developments, along with insight into current challenges and successful strategies for navigating this complex area.

Upon completion of the live registration, participants will gain access to the following:

• Live Event Access
• Presentation Slides